The U.S. Food and Drug Administration recently announced two developments that, taken together, mark a meaningful shift in how the agency is operationalizing artificial intelligence (AI) at the FDA: an expansion of its internal AI capabilities and the completion of a long‑running effort to consolidate FDA data systems into a unified platform. This announcement was framed as infrastructure—not as a new policy or regulatory position. That distinction matters. From FDA AI pilo